Cardamonin exerts selective therapeutic effects on RagC-mutant cells. Cardamonin can serve as a drug for individualised therapy for follicular lymphoma with RRAGC mutations.
The above results are in line with a constitutive overactivation of the mTORC1 pathway. Our study establishes de novo missense variants in RRAGC as cause of an early-onset mTORopathy with unfavorable prognosis.
over 2 years ago
Journal
|
RPS6 (Ribosomal Protein S6) • TFEB (Transcription Factor EB 2) • RRAGC (Ras Related GTP Binding C) • RRAGD (Ras related GTP binding)